Biopharmaceutical Fermentation Systems Market – Product Type (Upstream [Bioreactor, Bioprocess Analyzer], Downstream [Chromatography, Filtration]), Application (Recombinant Proteins, Antibiotics, Probiotics), End User – Global Forecast (2024 – 2032)

Biopharmaceutical Fermentation Systems Market Size

Biopharmaceutical Fermentation Systems Market size was valued at USD 11.5 billion in 2023 and is anticipated to showcase growth at 6% CAGR from 2024 and 2032. Growing demand for biopharmaceuticals, growing investments for developing new biopharmaceuticals and biosimilars, and increasing regulatory approvals for biopharmaceutical products is driving the demand for biopharmaceutical fermentation system market. Additionally, growing adoption of single use fermenters is also supporting the market growth.
 

Biopharmaceutical fermentation systems include the overall set of equipment, instruments, and procedures utilized for fermenting biological materials, such as microorganisms (such as bacteria, yeast, fungi) or cells (like mammalian or plant cells) to manufacture a diverse range of products. These systems can be complex or simple, based on the requirements and scale of the fermentation process.

Biopharmaceutical Fermentation Systems Market Trends

• Manufacturers are significantly investing in the development of advanced monitoring and control systems for biopharmaceutical fermentation. These systems incorporate real-time analytics, sensors, and automation technologies to facilitate accurate monitoring of critical process parameters, prompt identification of deviations, and the implementation of adaptive control strategies aimed at enhancing bioprocess efficiency and product quality.
   
• The adoption of single-use biopharmaceutical fermentation systems is increasing, due to its benefit over traditional reusable counterparts. For example, companies in biopharmaceuticals can streamline production processes by employing pre-sterilized components such as single-use bioreactors from manufacturers like Sartorius Stedim Biotech and Thermo Fisher Scientific Inc. These single use pre-sterilized components eliminate the need for time-consuming cleaning and sterilization between batches, reducing downtime and operational costs while ensuring product quality and safety.
   

Biopharmaceutical Fermentation Systems Market Analysis

Based on drug class, the market is segmented into upstream products and downstream products. The upstream products are further segmented into bioreactors/fermenters, bioprocess analyzers, process monitoring systems, and other upstream products. Similarly, the downstream products are further segmented into filtration & separation, chromatography, consumables & accessories, and other downstream products. The upstream products segment held the majority of market share in 2023 of about 62.2%.
 

• The dominating share of the upstream products segment can be attributed to increasing investments in biopharmaceutical research for the development of new and advanced therapies such as stem cell therapies, gene therapies and targeted therapies.
   
• Moreover, innovations in upstream products, such as the development of perfusion culture systems, single-use bioreactors, and c technologies, have transformed biopharmaceutical fermentation procedures. These technological breakthroughs are offering increased flexibility, scalability, and cost efficiency in bioproduction, leading to a surge in the demand for upstream products.
  
   

Based on application, the biopharmaceutical fermentation systems market is classified into recombinant proteins, antibiotics, probiotics, and other applications. The recombinant proteins segment dominated the market with a revenue of about USD 5 billion in 2023.
 

• Leading share of recombinant protein segment can be attributed to their increasing use across advanced therapies for cancer, autoimmune diseases, infectious diseases, genetic disorders, and rare diseases. The broad spectrum of therapeutic targets and indications for recombinant proteins drives demand for fermentation systems capable of producing a variety of protein-based biologics.
   
• Furthermore, recombinant proteins are among the high-value biologics that are offering significant revenue potential to the biopharmaceutical companies. The high cost of recombinant protein drugs, coupled with favorable reimbursement policies are increasing investment in fermentation systems capable of producing these biologics at large scale and with high purity, contributing to the dominating share of the segment.
   

Based on end user, the biopharmaceutical fermentation systems market is classified into biopharmaceutical companies, contract research organizations, academic research institutes, and other end users. The biopharmaceutical companies segment secured a leading share of about 42.3% in 2023 and is anticipated to grow at 5.9% CAGR during the forecast period.
 

• Increasing investments by biopharmaceutical companies in research and development for developing advanced biologic therapies, including monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and gene therapies is contributing to an increased demand for biopharmaceutical fermentation systems.
   
• Moreover, owing to increased production demands, the biopharmaceutical companies are focusing towards expanding their existing in-house manufacturing capabilities, which is contributing to the leading share of biopharmaceutical companies’ segment.
   

North America biopharmaceutical fermentation systems market accounted for 41.4% of market share in global market in 2023 and is predicted to reach USD 7.7 billion by 2032.
 

• Presence of large number of biopharmaceutical companies in the country offering advanced treatment options such as targeted therapies, gene therapies, stem cell therapies is driving the revenue growth in the region. Biopharmaceutical fermentation systems manufacturers are leveraging their manufacturing expertise, research and development capabilities, and marketing strategies to maintain dominance in the regional market, which has eased the availability of advanced biopharmaceutical fermentation systems for the biopharmaceutical companies in the region.
   
• Large number of approvals for biopharmaceutical products by regulatory authorities such as U.S. FDA and Health Canada is contributing to an increased demand to produce new biopharmaceutical and biosimilars, thereby driving the demand for biopharmaceutical fermentation systems.
   

The U.S. biopharmaceutical fermentation systems market was valued at USD 4.2 billion in 2023 and is anticipated to grow at a CAGR of 5.7% over the forecast period.
 

• Increasing investments in biopharmaceutical-based clinical research and growing demand for personalized therapies is driving the revenue growth in U.S. market. For instance, according to the American Society of Gene & Cell Therapy, In the first quarter of 2023, companies in US signed 110 deals to promote advancements in gene therapies.  
   
• Availability of reimbursement and coverage for biopharmaceutical products is further contributing to their increasing adoption in the country. Increasing demand for biopharmaceuticals has led the biopharmaceutical companies to expand their existing manufacturing capabilities, thereby driving the demand for higher capacity biopharmaceutical fermentation systems.
   

Germany biopharmaceutical fermentation systems market is expected to show significant growth during the forecast period.
 

• Germany’s thriving biopharmaceutical sector benefits from substantial investments in research and development, driving innovation in bioprocessing technologies such as fermentation systems, which in turn fuels market expansion. According to the Germany Trade & Invest (GTI), Germany has about 774 biotechnology companies in 2021, that participated in research projects with partners from academic and research institutes. Increasing investments for the research and development in novel biopharmaceutical therapies are propelling the demand for biopharmaceutical fermentation systems in the Germany.
   
• Furthermore, government in Germany are prioritizing the development in biotechnology and biopharmaceutical sector. “BioRegions” a cluster initiative for the advancements of modern biotechnology in Germany is driving the infrastructural developments from technology parks to statewide organizations. Such initiatives from government are driving the demand for bioprocessing systems such as biopharmaceutical fermentation systems in Germany.
   

India biopharmaceutical fermentation systems market is anticipated to grow remarkably over the coming years.
 

• Increasing growth in chronic illnesses such as diabetes, cancer, and liver fibrosis, along with improved access to advanced treatment modalities such as biosimilars and personalized therapies is driving the revenue growth in biopharmaceutical market in India. Together with boost for local production of biopharmaceuticals, the demand for high-capacity biopharmaceutical fermentation systems has surged in the country.
   
• Moreover, the government of India has prioritized local production of biopharmaceuticals including advanced vaccines for COVID-19, cholera, Japanese encephalitis, neglected tropical diseases, rabies, and tuberculosis. Growing government investments coupled with interest of private companies such as Biological E and Serum Institute of India, has transformed the country as a leading vaccine manufacturer. With an increasing growth in chronic diseases, the demand for biopharmaceutical products such as vaccines is increasing, thereby driving the demand for biopharmaceutical fermentation systems.
   

Biopharmaceutical Fermentation Systems Market Share

The market is moderately fragmented. Established market players have been focusing towards launching new fermentation systems with advanced features such as advanced control units and single-use capabilities. Furthermore, established companies have substantial manufacturing expertise and experience, that they are leveraging to enhance their product features. Small companies are adopting lower pricing strategies and are focusing towards offering fermentation systems for the specific applications to remain competitive, which has contributed to the overall diversity in the market.
 

Biopharmaceutical Fermentation Systems Market Companies

Prominent players operating in the biopharmaceutical fermentation systems industry include:

• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bioengineering AG
• Cellexus Limited
• Danaher Corporation
• Eppendorf AG
• F. Hoffmann-La Roche Ltd.
• GE HealthCare Technologies, Inc. 
• Getinge Group
• Lonza Group AG
• Merck KGaA
• Nova Biomedicals
• Sartorius Stedim Biotech
• Thermo Fisher Scientific Inc.
• ZETA
   

Biopharmaceutical Fermentation Systems Industry News:

• In April 2023, Cytiva, a subsidiary of Danaher Corporation, launched X-platform bioreactors aimed at streamlining single-use upstream bioprocessing operations. These bioreactors, initially offered in sizes of 50 and 200 liters, were equipped with Figurate automation solution software, facilitating enhanced process efficiency through ergonomic enhancements.
   
• In March 2022, Cellexus announced a partnership with Verder Liquids to provide acid/base pumps integrated with their CellMaker Low Flow and Plus bioreactor systems. This helped the company upgrade its products and strengthen its market offerings with additional benefits.
   

The biopharmaceutical fermentation systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product type

• Upstream products
  • Bioreactors/fermenters
  • Bioprocess analyzers
  • Process monitoring systems
  • Other upstream products
• Downstream products
  • Filtration & separation
  • Chromatography
  • Consumables & accessories
  • Other downstream products

Market, By Application

• Recombinant proteins
• Antibiotics
• Probiotics
• Other applications

Market, By End user

• Biopharmaceutical companies
• Contract research organizations
• Academic research institutes
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa